Metastasis to and from the central nervous system–the ‘relatively protected site’

Subramanian, Anuradha; Harris, A.L.; Piggott, Kisha; Shieff, Colin; Bradford, Robert

doi:10.1016/s1470-2045(02)00819-7

Cited by 115 publications

(115 citation statements)

References 33 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…31 Patients are typically in an advanced stage of their disease and have already been exposed to multiple chemotherapy regimens. 32 The same can be said of our patients, who had all been exposed to radiation therapy and to multiple chemotherapy regimens (average of 4).…”

Section: Breast Metastasismentioning

confidence: 63%

Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in the treatment of cerebral metastasis

Fortin

Gendron

Boudrias

et al. 2007

Cancer

View full text Add to dashboard Cite

Cationic polyurethane‐fluorinated acrylate hybrid dispersions (PUFA) were prepared by the copolymerization of styrene, butyl acrylate, and 2,2,3,4,4,4‐hexafluorobutyl methacrylate in the medium of crosslinked polyurethane via phase inversion polymerization. The said polyurethane was synthesized in acetone from 2,4‐tolyene diisocyanate, N‐methyldiethanolamine, trimethylolpropane, and soft polyester diol block. The influences of hydrophilic monomer on the surface properties, immersion behaviors, particle size and, zeta potential of the dispersions were investigated. The results show that the addition of hydrophilic monomer can be advantaged to the stability of dispersions and yet will increase the surface free energy by more than 19.9%. The PUFA coating films cured at ambient conditions have the lower surface free energy (less than 0.02033 J/m2). At the same time, there is an obvious mobility of fluorinated groups in fluorinated polymer films. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

show abstract

Section: Breast Metastasismentioning

confidence: 63%

Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in the treatment of cerebral metastasis

Fortin

Gendron

Boudrias

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…Although cell migration within the neural parenchyma is a common feature of gliomas, it is almost never observed in other tumors that metastasize to the central nervous system, even when those tumors may aggressively invade their tissue of origin (42). At the same time, the migratory ability of gliomas is restricted to central nervous tissue.…”

Section: Discussionmentioning

confidence: 99%

“…At the same time, the migratory ability of gliomas is restricted to central nervous tissue. Gliomas very rarely metastasize and, when implanted experimentally in nonnervous tissue, they grow as encapsulated, noninfiltrative masses (42,43). This suggests that a combination of glioma-specific molecular mechanisms and the particular composition of the neural microenvironment may underlie the unique ability of these tumors to disperse in the central nervous system.…”

Section: Discussionmentioning

confidence: 99%

The Proteoglycan Brevican Binds to Fibronectin after Proteolytic Cleavage and Promotes Glioma Cell Motility

Kong

Matthews

et al. 2008

Journal of Biological Chemistry

View full text Add to dashboard Cite

The adult neural parenchyma contains a distinctive extracellular matrix that acts as a barrier to cell and neurite motility. Nonneural tumors that metastasize to the central nervous system almost never infiltrate it and instead displace the neural tissue as they grow. In contrast, invasive gliomas disrupt the extracellular matrix and disperse within the neural tissue. A major inhibitory component of the neural matrix is the lectican family of chondroitin sulfate proteoglycans, of which brevican is the most abundant member in the adult brain. Interestingly, brevican is also highly up-regulated in gliomas and promotes glioma dispersion by unknown mechanisms. Here we show that brevican secreted by glioma cells enhances cell adhesion and motility only after proteolytic cleavage. At the molecular level, brevican promotes epidermal growth factor receptor activation, increases the expression of cell adhesion molecules, and promotes the secretion of fibronectin and accumulation of fibronectin microfibrils on the cell surface. Moreover, the N-terminal cleavage product of brevican, but not the full-length protein, associates with fibronectin in cultured cells and in surgical samples of glioma. Taken together, our results provide the first evidence of the cellular and molecular mechanisms that may underlie the motility-promoting role of brevican in primary brain tumors. In addition, these results underscore the important functional implications of brevican processing in glioma progression.Malignant gliomas are primary tumors of the central nervous system with an almost invariably rapid and lethal outcome. Current treatments for gliomas fail to remove the invasive cells that remain diffusely embedded within normal tissue even after aggressive surgical and postsurgical treatment (1). The dispersion of glioma cells is the major cause of disease progression after initial treatment and, therefore, of therapeutic failure.The ability of glioma cells to disperse within the mature central nervous system is unusual, because adult neural tissue is predominantly inhibitory to process extension and cell movement (2, 3). One of the major barriers to cellular movement in the central nervous system is the neural extracellular matrix (ECM).2 This matrix is primarily composed of a scaffold of hyaluronic acid (HA) and associated glycoproteins, with a remarkable absence of fibrillar proteins that support cell motility (2, 4). The inhibitory nature of the neural ECM has been largely attributed to a family of chondroitin sulfate proteoglycans that bind and organize HA within the ECM: aggrecan, neurocan, versican, and brevican, collectively known as lecticans (5-7). It is thought that, to overcome this barrier to movement, glioma cells degrade the normal ECM (8, 9) and secrete mesenchymal matrix components that promote cell adhesion and motility, such as fibronectin and collagens (10 -13). However, surprisingly, gliomas also express large amounts of the inhibitory lecticans versican (14) and brevican (15, 16).Brevican, also known as brain-enrich...

show abstract

“…An estimated 150,000 patients are diagnosed with brain metastases every year, and non-small cell lung cancer (NSCLC) is the most common primary site for secondary brain metastasis (Subramanian et al, 2002;Nathoo et al, 2005;Bovi and White, 2012). With advanced therapy and increased use of combined-modality therapy, the distant metastases of lung cancer have been reduced and overall survival has improved.…”

Section: Introductionmentioning

confidence: 99%

Role of TGFB1 polymorphism in the development of metastatic brain tumors in non-small cell lung cancer patients

Wang¹,

Song²,

Liu³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study to investigate the role of 3 single-nucleotide polymorphisms of the gene encoding transforming growth factor-b1 (TGFB1) in the development of metastatic brain tumors in non-small cell lung cancer patients. The polymorphisms in TGFB1 rs4803455, rs1800469, and rs1800470 were evaluated by polymerase chain reaction-restriction fragment length polymorphism. Odds ratios and their corresponding 95% confidence intervals were used to assess the influence of TGFB1 rs4803455, rs1800469, and rs1800470 on metastatic brain tumors. We found that cases were more likely to have a later disease stage when compared with control subjects, without brain metastasis. Individuals carrying the TGFB1 rs1800469 TT and CT+TT genotypes had an increased risk of developing brain metastasis compared with the rs1800469 CC genotype. Moreover, a significant interaction was observed between the rs1800469 polymorphism and disease stage. However, no significant association between polymorphisms rs4803455 and rs1800470 and the risk of developing brain metastasis were observed. We found that the TGFB1 rs1800469 polymorphism may be predictive biomarker for the risk of developing brain metastasis in non-small cell (2015) lung cancer patients.

show abstract

Metastasis to and from the central nervous system–the ‘relatively protected site’

Cited by 115 publications

References 33 publications

Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in the treatment of cerebral metastasis

Enhanced chemotherapy delivery by intraarterial infusion and blood‐brain barrier disruption in the treatment of cerebral metastasis

The Proteoglycan Brevican Binds to Fibronectin after Proteolytic Cleavage and Promotes Glioma Cell Motility

Role of TGFB1 polymorphism in the development of metastatic brain tumors in non-small cell lung cancer patients

Contact Info

Product

Resources

About